StudyFinder

HM2026-09: Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma who Have Received 1-3 Prior Lines of Therapy (Trilogy5)

Status: Recruiting

The purpose of this study is to evaluate a new study drug, JNJ-79635322, in adults with multiple myeloma that has returned after treatment or has not responded to previous treatment. Participants must have received 1 to 3 prior lines of therapy, including lenalidomide and an anti-CD38 antibody. Researchers want to learn how safe the study drug is and how well it works compared with the current standard treatment for multiple myeloma.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosed with multiple myeloma
• have multiple myeloma that has come back or has not responded to treatment
• have received at least 3 prior lines of treatment, including a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-CD38 antibody
• see the ClinicalTrials.gov listing for complete inclusion criteria
Exclusion Criteria:

• have an active hepatitis infection
• have multiple myeloma that has spread to the brain or central nervous system
• have certain allergies to the study medications or their ingredients
• have had major surgery within the past 2 weeks, are still recovering from surgery, or have surgery planned during the study
• have received or plan to receive a live vaccine within 4 weeks before starting the study or during study treatment
• see the ClinicalTrials.gov listing for complete exclusion criteria
Conditions:

Blood Disorders, Cancer

Keywords:

Clinics and Surgery Center (CSC), blood cancer, blood disorders, MM, Multiple Myeloma

Study Contact: Eric Homan - homa0030@umn.edu
Principal Investigator: Daniel O'Leary
Phase: PHASE3
IRB Number: STUDY00028442
See this study on ClinicalTrials.gov

Back